Lowe Brockenbrough & Co. Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 2.9% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 108,752 shares of the company’s stock after selling 3,200 shares during the quarter. Johnson & Johnson accounts for 2.2% of Lowe Brockenbrough & Co. Inc.’s investment portfolio, making the stock its 6th biggest holding. Lowe Brockenbrough & Co. Inc.’s holdings in Johnson & Johnson were worth $14,139,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also modified their holdings of JNJ. Vanguard Group Inc. increased its holdings in shares of Johnson & Johnson by 1.5% during the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after acquiring an additional 3,023,110 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Johnson & Johnson by 2.6% during the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after acquiring an additional 4,332,612 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Johnson & Johnson by 0.4% during the third quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after acquiring an additional 130,437 shares in the last quarter. FMR LLC increased its holdings in shares of Johnson & Johnson by 5.9% during the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after acquiring an additional 1,509,745 shares in the last quarter. Finally, Capital World Investors increased its holdings in shares of Johnson & Johnson by 4.1% during the second quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after acquiring an additional 1,050,000 shares in the last quarter. 65.53% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have recently commented on JNJ shares. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price objective for the company in a report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Stifel Nicolaus boosted their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Citigroup boosted their price objective on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a report on Monday, October 23rd. Finally, Wells Fargo & Co restated an “outperform” rating and set a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $146.16.
Johnson & Johnson (JNJ) opened at $133.15 on Friday. The stock has a market capitalization of $357,710.00, a price-to-earnings ratio of 341.41, a price-to-earnings-growth ratio of 2.20 and a beta of 0.74. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 12 month low of $118.05 and a 12 month high of $148.32.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. The firm had revenue of $20.20 billion during the quarter, compared to the consensus estimate of $20.08 billion. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.58 EPS. equities research analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be paid a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 861.54%.
COPYRIGHT VIOLATION WARNING: This piece was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/02/18/johnson-johnson-jnj-is-lowe-brockenbrough-co-inc-s-6th-largest-position.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.